In RA patients, the ACPA response is known to be heterogeneous, different RA patients display reactivities against different citrullinated peptides and proteins, and there is large interindividual variability in ACPA reactivities [19–21]. This evidence concerns the gene PRTN3 and rheumatoid arthritis.